Insulet is trading 15.13% up at $167.01 after closing at $145.06 on August 12, 2026; no clear company-specific catalyst explaining the after-hours surge was identified.
- The August 12 securities-lawsuit alert was negative and concerned alleged Omnipod safety misstatements.
- Recent earnings guidance had already been published.
- Broader markets were modestly higher, including the Nasdaq Composite at +0.55%, but that does not explain the full move.